TERZI Fabiola : UMR_S11151 UMR8253 : Mechanisms and therapeutic strategies of chronic kidney disease

Unit : INSERM UMR_S1151 - CNRS UMR8253 - Institut Necker Enfants Malades (INEM) - Université Paris Descartes

Hôpital Necker Enfants Malades
INSERM UMR_S1151 - CNRS UMR8253
Equipe F. TERZI
Tour Lavoisier, 6ème étage
149 rue de Sèvres
75015 PARIS

Speciality : Department BCMPP

Director of the unit : Xavier NASSIF

Principal investigator :

TERZI Fabiola
Email : fabiola.terziSPAMFILTER@inserm.fr Phone number: +33 (0)1 44 49 52 45

Composition of research team :

  • TERZI Fabiola (DR1-INSERM, HDR)           
  • LAOUARI Denise (CR1-INSERM)         
  • GALLAZZINI Morgan (CR1-INSERM )     
  • LEGENDRE Christophe (PU-PH, HDR)
  • KNEBELMANN Bertrand (PU-PH, HDR)
  • JOLY Dominique (PU-PH, HDR)         
  • ANGLICHEAU  Dany (PU-PH, HDR)         
  • CANAUD Guillaume (MCUPH )     
  • EL KAROUI Khalil (CCA)  

5 Recent publications of the research team :

Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a novel therapeutic approach. Nat Med 2005, 11, 867-874.

Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Berger T, Mak TW, Knebelmann B, Friedlander G, Barasch J, Terzi F. Lipocalin 2 is essential in chronic kidney disease progression in mice and humans. J Clin Invest 2010, 120, 4065-4076.

Laouari D, Burtin M, Phelep A, Bienaime F, Noel LH, Lee DC, Legendre C, Friedlander G, Pontoglio M, Terzi F. A transcriptional network underlies susceptibility to kidney disease progression. EMBO Mol Med 2012, 4, 825-839

Canaud G, Bienaimé F, Viau A, Treins C, Baron W, Nguyen C, Burtin M, Berissi S, Giannakakis K, Onetti Muda A, Zschiedrich S, Huber TB, Friedlander G, Legendre C, Pontoglio M, Pende M, Terzi F. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med 2013, 19, 1288-1296.

Canaud G, Bienaimé F, Tabarin F, Bataillon G, Seilhean D, Noel LH, Dragon-Durey M, Snanoudj R, Friedlander G, Halbwachs-Mecarelli L, Legendre C, Terzi F. mTORC Pathway Inhibition in Antiphospholipid Antibody Syndrome. New Eng J Med 2014, in press.